Folate and vitamin D during pregnancy: association for reducing pregnancy complications

Objective. To evaluate the efficacy of supplementation with Folervid® during pregnancy.
Materials and Methods. Observational cohort of women who received daily oral supplementation of Folervid® during pregnancy starting from the first trimester of pregnancy, who were compared with a control group who did not. Folervid® contained Vitamina C 220 mg; Vitamin B12 2.5 mcg; Vitamin B6 1.4 mcg; Vitamin D 50 mcg (2,000 UI); Folate 400 mcg as 5-Methyl-tetrahydrofolate. The primary outcome was the incidence of preeclampsia.
Results. 100 women met the inclusion criteria and were included in the study. This cohort was compared with a matched control group of 100 controls.
Conclusions. Women who received Folervid® during pregnancy had significantly lower risk of preterm birth at less than 37 weeks of gestation, and first trimester abortion.

Table of Content: Vol. 35 (Supplement No. 1) 2023 – Conference Proceedings

Remember that the download is free only for personal use. If you want to utilize articles for large distribution, please contact us at